MaxCyte IPO Presentation Deck
Continued Investment in Cell Therapy
1,800+
Cell and gene therapies in
development globally
Source: ASGCT - Pharma Intelligence
July 2021
WW Product Sales: US
<-700
Genetically-modified cell
therapies in development
Source: Evaluate Pharma
Projected sales of gene-modified cell therapies by 2026
12,000
10,000
8,000
6,000
4,000
2,000
0
(սյա)$
40+
Allogeneic companies with
assets in development
Source: William Blair Research
2020 2021 2022
Source: Evaluate Pharma
2023 2024 2025 2026
CONFIDENTIAL
Total amount of 2020 global
financings for cell and gene
therapy companies
$19.9B
Source: Alliance for Regenerative Medicine
First next-generation engineered
cell therapy expected to be
approved in
2023 2024
Source: Evaluate PharmaView entire presentation